A M55V polymorphism in the SUMO4 gene is associated with a reduced prevalence of diabetic retinopathy in patients with type 1 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 1, 2008, Pages 14-17

  Rudofsky Jr , G ^a,b   Schlotterer, A ^a   Humpert, P M ^a   Tafel, J ^a   Morcos, M ^a   Nawroth, P P ^a   Bierhaus, A ^a   Hamann, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Division of Endocrinology and Metabolism   (Germany)

Author keywords

Diabetic retinopathy; Polymorphism; Small ubiquitin related modifiers; SUMO4; Type 1 diabetes

Indexed keywords

SUMO 4 PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; RISK ASSESSMENT; SUMO4 GENE;

ADULT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 39449135080     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985357     Document Type: Article

References (23)

1. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6910-6924
2. Bierhaus A, Humpert PM, Rudofsky G, Wendt T, Morcos M, Hamann A, Nawroth PP. New treatments for diabetic neuropathy: pathogenetically oriented treatment. Curr Diab Rep 2003; 3: 452-458
3. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type 1 diabetes mellitus. J Biol Chem 2004; 279: 27233-27238
4. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454
5. DCCT Research Group. Factors in the development of diabetic neuropathy Baseline analysis of neuropathy in feasibility phase of diabetic control and complications trials. Diabetes 1988; 37: 471-481
6. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaB alpha inhibits NF-kappaB activation. Mol Cell 1998; 2: 233-239
7. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods in press
8. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004; 36: 837-841
9. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299
10. Hay RT, Vuillard L, Desterro JM, Rodriguez MS. Control of NF-kappa B transcriptional activation by signal induced proteolysis of 1 kappa B alpha. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1601-1609
11. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A, Nawroth PP. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999; 42: 222-232
12. Lin HY, Wang CL, Hsiao PJ, Yung-Chuan L, Chen SY, Lin KD, Hsin SC, Hsieh MC, Shin SJ. SUMO4 M55V Variant Is Associated with Diabetic Nephropathy in Type 2 Diabetes. Diabetes 2007; 56: 1177-1180
13. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999; 10: 157-167
14. Noso S, Ikegami H, Fujisawa T, Kawabata Y, Asano K, Hiromine Y, Tsurumaru M, Sugihara S, Lee I, Kawasaki E, Awata T, Ogihara T. Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes. Diabetes 2005; 54: 3582-3586
15. Pichler A, Melchior F. Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport. Traffic 2002; 3: 381-387
16. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823
17. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a pro-apoptotic program in retinal pericytes. Diabetes 2002; 51: 2241-2248
18. Rudofsky Jr G, Isermann B, Schilling T, Schiekofer S, Andrassy M, Schneider JG, Morcos M, Humpert PM, Sayed AA, Witte S, Renn W, Pfohl M, Hamann A, Nosikov V, Schleicher E, Haring HU, Rudofsky G, Ritz E, Nawroth PP, Bierhaus A. A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112: 135-141
19. Vassileva MT, Matunis MJ. SUMO modification of heterogeneous nuclear ribonucleoproteins. Mol Cell Biol 2004; 24: 3623-3632
20. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Inves 2005; 115: 1111-1119
21. Wong T, Mitchell P. The eye in hypertension. Lancet 2007; 369: 425-435
22. Yamamoto Y, Gaynor RB. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 2004; 29: 72-79
23. Zheng L, Szabo C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004; 53: 2960-2967